³ª´®ÅÍ
°øÁö»çÇ×
ÀÇÇÐÁ¤º¸
º¹ÁöÁ¤Ã¥
ȯ¿ìȸ¼Ò½Ä
ȸºñ ¹× ÈÄ¿ø±Ý ³³ºÎ³»¿ª
ÇåÆÃÅϺ´ ¸Þ´º¾ó
HOME > ³ª´®ÅÍ > ÀÇÇÐÁ¤º¸

ÀÛ¼ºÀÚ
huntington [ÀÛ¼ºÀÏ : 2016-09-23 15:48:40 ]   
Á¦¸ñ Teva Á¦¾àȸ»ç¿¡¼­ ÁøÇàÁßÀÎ ÀÓ»ó½ÃÇè ¼Ò½ÄÀ» ÀüÇص帳´Ï´Ù.

½Å°æº¸È£È¿°ú °³¼±À» À§ÇÑ ¾à(Pridopidine)À¸·Î ÇöÀç 2ÀÓ»ó½ÃÇè Áß¿¡ ÀÖÀ¸¸ç ÇåÆÃÅϺ´ Áõ»óÀ» ´ÊÃß´Â È¿°ú¸¦ º¸Àδٰí ÇÕ´Ï´Ù.


¾ÆÁ÷Àº ÀÓ»ó½ÃÇè ´Ü°èÀÎ ¾àÀ̸ç Ãß°¡ ÀÓ»ó½ÃÇè ´Ü°èµîÀÇ °á°ú³ª¿À¸é ¼Ò½ÄÀüÇص帮°Ú½À´Ï´Ù.





Trial finds Teva drug could slow Huntington's disease

 

http://www.globes.co.il/en/article-teva-pridopidine-could-slow-huntingtons-d

isease-1001153229

 

Globes Correspondent 09/19/2016

 

 

 

Teva Pharmaceutical Industries Ltd. <http://www.tevapharm.com/>  today

announced what could be a major breakthrough in the treatment of

Huntington's Disease (HD) with positive results from its exploratory Phase

II PRIDE-HD study. The trial found a statistically significant impact on the

endpoint of the progression of Huntington Disease at 52 weeks following

treatment with Pridopidine at certain doses versus placebo. The effect of

Pridopidine was further evident in a sub-population of patients with early

stage HD, an effect first observed at 26 weeks.

 

 

 

"Slowing down the progression of this disease has proven to be impossible

until now. These findings give us a reason to believe we may be finally

making progress in slowing deterioration of disease," said Spyros

Papapetropoulos, Teva's VP Clinical Development, Neurodegenerative Diseases.

 

 

 

 

This was a 52-week, dose-ranging trial of Pridopidine twice daily versus

placebo, in the treatment of Huntington disease (HD). The study was directed

at measuring improvement in motor function and the effect on HD progression.

An unusually high placebo effect, extending beyond that expected from

previous studies, limited the ability to determine treatment effects on

assessments of HD motor scores. Evidence of symptomatic impact, however, was

seen in the early stage HD patient sub-population, with improvement in Total

Motor Score (TMS) and dystonia observed at 26 and 52 weeks in this patient

sub-set (stage 1 HD) at specific doses.

 

 

 

The discovery of Pridopidine's previously unknown mode of action as a potent

agonist of the Sigma 1 Receptor (S1R) resulted in a change in PRIDE-HD study

design, from a 26-week study focused on symptoms, to a 52-week study focused

on exploring pridopidine's potential impact on disease progression, as

measured by Total Functional Capacity (TFC).

 

 

 

"I am encouraged by these results, which provide us with clear insights into

the approach to be taken in Phase III development", said Michael Hayden,

President of Teva Global R&D and Chief Scientific Officer. "My obvious hope

is that this will provide the HD community with a medicine capable of

slowing down the progression of this devastating disease."

 

 

 

"These study results are very important for the HD community and for the

continued development of pridopidine. Firstly, pridopidine's safety profile

has been confirmed and extended. Secondly, we now have a clearer idea of the

dosages to study in Phase 3. Lastly, we have some of the most encouraging

evidence to date about an intervention which may slow the inexorable

functional decline of HD," said Karl Kieburtz, M.D., M.P.H., Director of the

Clinical & Translational Science Institute at the University of Rochester

Medical Center.

 

 

 

The results seen in this exploratory study will need to be confirmed in a

Phase III program that will be developed in collaboration with relevant

regulatory agencies.

 

 

 

Pridopidine is an investigational, oral small molecule being developed for

the treatment of HD that exerts its effect as an agonist of S1R. S1R plays a

key role in neuroprotection through increased production of brain-derived

neurotrophic factor (BDNF). Levels of BDNF are decreased in HD and other

neurodegenerative disorders including Parkinson's disease, Alzheimer's

disease and ALS.

 

================================

 

 

 

Huntington Study Group PRIDE HD Study Information:

http://huntingtonstudygroup.org/current-clinical-trials/pride-hd-study/

 

.       No information available yet on enrolling for the Phase 3 study.

 

.       No facilities in Florida participated in the Phase II study:

https://clinicaltrials.gov/ct2/show/study/NCT02006472?show_locs=Y#locn

 

[ »õ±Û | ´ä±Û | ¼öÁ¤ | »èÁ¦ ] [ ¸ñ·Ï ]
[ ÃѰԽù° : 120 | page : 6 ]
[ Á¤·ÄÁ¶°Ç : µî·ÏÀÏ | Á¶È¸  ]
¼ø¹ø Á¦¸ñ Á¶È¸ ÆÄÀÏ µî·ÏÀÏ ÀÛ¼ºÀÚ
100   ù ¹ø° Huntingtin ÀúÇÏ ¿¬±¸ °£Ç๰ÀÇ »õ·Î¿î ¾÷µ¥ÀÌÆ® 676 20/06/10 ¿î¿µÀÚ  
99   ³ú¸¦ °¨½Ñ ¾×ü¿¡¼­ À¯ÇØÇÑ ÇåÆÃƾ ´Ü¹éÁúÀÇ ÃøÁ¤ 641 20/07/30 ¿î¿µÀÚ  
98   ´ë±Ô¸ð ¿¬±¸¸¦ ÅëÇÑ ÇåÆÃÅϺ´¿¡¼­ »õ·Î¿î À¯ÀüÀû º¯ÀÌ(genetic modifie 632 20/07/10 ¿î¿µÀÚ  
97   ´õ ³ÐÀº °üÁ¡À¸·Î º» ÇåÆÃÅϺ´ÀÇ ÀÌ»ó¿îµ¿¿Ü Áõ»óµé 677 20/08/29 ¿î¿µÀÚ  
96   ÀüÀÚºöÀÌ ÇåÆÃÅϺ´ ´Ü¹éÁúÀÇ ÃÖ»óÀÇ À̹ÌÁö¸¦ º¸¿©ÁØ´Ù. 602 20/08/06 ¿î¿µÀÚ  
95   ´Ù¼Ò ±ä CAG ¹Ýº¹Àº ¿ì¸®°¡ »ý°¢ÇÑ °Íº¸´Ù ´õ ÀϹÝÀûÀÌ´Ù 667 20/09/18 ¿î¿µÀÚ  
94   Áö¿ø½Ã½ºÅÛÀÇ ¹®Á¦ ¹ß»ý - ½Å°æ±³¼¼Æ÷°¡ ÇåÆÃÅϺ´ Áõ»ó¿¡ °ü¿©ÇÑ´Ù 602 20/09/01 ¿î¿µÀÚ  
93   DeutetrabenazineÀ» ÀÌ¿ëÇÑ ÇåÆÃÅϺ´ Ä¡·á: ±àÁ¤ÀûÀÎ ÀÓ»ó½ÃÇè ±×·¯³ª 747 20/10/19 ¿î¿µÀÚ  
92   ±ØµµÀÇ µå¹® µ¹º¯ÀÌ°¡ ³ú ¹ß´Þ¿¡¼­ ÇåÆÃÅϺ´ À¯ÀüÀÚÀÇ Á߿伺À» Á¦½ÃÇÔ 611 20/10/06 ¿î¿µÀÚ  
91   Á˼ÛÇÕ´Ï´Ù ¿©·¯ºÐ, PRIDE-HD ÀÓ»ó½ÃÇè¿¡¼­ PridopidineÀÌ ÇåÆÃÅϺ´ÀÇ 589 20/11/29 ¿î¿µÀÚ  
90   ÇåÆÃÅϺ´ÀÇ Â÷¼¼´ë °Ô³ð ÆíÁý µµ±¸ÀÇ Áß¿äÇÑ ¹ßÀü 582 20/11/06 ¿î¿µÀÚ  
89   È­ÀÌÀÚÀÇ ¾Æ¸¶¸±¸®½º ½ÃÇèÀº ºÎÁ¤Àû °á°ú·Î Á¾·áµÊ: ÇåÆÃÅϺ´ÀÇ Áõ»ó °³... 581 18/12/16 ¿î¿µÀÚ  
88   °­·ÂÇÑ ¸Þ½ÃÁö: µ¶¼º RNA ¸Þ½ÃÁö ºÐÀÚ°¡ ÇåÆÃÅϺ´¿¡ Çظ¦ ³¢Ä¥ ¼ö ÀÖÀ» 763 20/12/03 ¿î¿µÀÚ  
87   ¿¹¿Üµµ ¾µ¸ð°¡ ÀÖ´Ù - ÇåÆÃÅϺ´ÀÇ ¹ßº´ ¹× ÁøÇàÀ» ÀÌÇØÇϱâ À§ÇÏ¿© ¿¹¿Ü... 608 21/01/19 ¿î¿µÀÚ  
86   ÇåÆÃÅϺ´À» ÅëÇØ º¸¿©Áö´Â ¼¼Æ÷ À̵¿ÀÇ Á߿伺 650 21/01/05 ¿î¿µÀÚ  
85   ÇåÆÃƾÀÌ ¸ÁÄ¡¸¦ µé¾ú´Ù: ÇåÆÃÅϺ´¿¡¼­ DNA º¹±¸ 676 21/02/24 ¿î¿µÀÚ  
84   À߸øµÈ Áø½Ç: ´ë¸¶ÃÊ´Â ÇåÆÃÅϺ´À» Çâ»ó½Ãų ¼ö ÀÖÀ»±î? 574 21/02/03 ¿î¿µÀÚ  
83   ¹«¸®¸¦ À̲ô´Â ¾ç : ÇåÆÃÅϺ´¿¡¼­ ½ÅÁø ´ë»ç ¹× ¹ÙÀÌ¿À ¸¶Ä¿ 571 21/03/19 ¿î¿µÀÚ  
82   FDA ÇåÆÃÅÏ Áúº´ÀÇ Áõ»ó¿¡ ´ëÇÑ ½Å¾à ½ÂÀÎ 585 21/03/03 ¿î¿µÀÚ  
81   °ÔÀÌÆ®¿¡ Á¸ÀçÇÏ´Â Àû –ÇÙ ¼ö¼ÛÀ» ¹æÇØÇÏ´Â ÇåÆÃƾ 586 21/04/22 ¿î¿µÀÚ  

1 2 3 4 5 6 [ »õ±Û | óÀ½¸ñ·Ï | ¸ñ·Ï ]  
´Üü¸í : ÇåÆÃÅϺ´ ȯ¿ìȸ   ÁÖ¼Ò : ¼­¿ï½Ã Á¾·Î±¸ ¿¬°Çµ¿ ¼­¿ï´ëÇб³º´¿ø  

Copyright¨Ï by huntington.co.kr All rights reserved.    webmaster  °³ÀÎÁ¤º¸ Ãë±Þ¹æħ